Recent Updates
Recently added Catalysts
SLDB

Solid Biosciences Provides Fourth Quarter And Full Year 2022

Thursday, March 23, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Solid Biosciences Provides Fourth Quarter And Full Year 2022
Price reaction · baseline $3.78 (2023-03-22 close) · hit after-hours · clean, no other SLDB news in the window
day 0 close
-0.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
7.4%
average across 7 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
carmustine
Phase 3 · Lymphoma

Full Press Release Details

Solid Biosciences Provides Fourth Quarter And Full Year 2022.
ShareAdd on Google
Tags: SLDB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Mar 23, 2023

Biotech snapshot

Cash runway
$378M liquidity · $18M/mo burn
~21 mo
Low dilution risk
Lead asset
carmustinePhase 3
Lymphoma →

Catalyst track record

+116%
best trade around SLDB's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for SLDB.

See every catalyst's timing & PoA →